PeerVoice Oncology & Haematology Video

Jan 13 2025 180 ep. 24 mins 788
PeerVoice Oncology & Haematology Video Podcast artwork

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  Science  Health & Fitness  Education
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments

Jan 13 2025 12 mins  
Visit https://www.peervoice.com/TJF860 to view the entire programme with slides. After completing “Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments”, participants will be able to: Outline current treatment recommendations for the management of refractory metastatic colorectal cancer (mCRC); Analyze the clinical evidence o

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Dec 27 2024 42 mins  
Visit https://www.peervoice.com/YJY860 to view the entire programme with slides. After completing “Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC”, participants will be able to: Summarise the unmet needs in the management of patients with relapsed or refractory (R/R) metastatic colorectal cancer (mCRC);

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

Dec 13 2024 9 mins  
Visit https://www.peervoice.com/RBQ860 to view the entire programme with slides. After completing “Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion”, participants will be able to: Describe the incidence and underlying pathophysiology of MEK-inhibitor—associated serous retinopathy

Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma

Dec 13 2024 18 mins  
Visit https://www.peervoice.com/TBT860 to view the entire programme with slides. After completing “Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma”, participants will be able to: Discuss the latest evidence with immunotherapy-based combinations in the first-line treatm

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Dec 13 2024 10 mins  
Visit https://www.peervoice.com/DFF860 to view the entire programme with slides. After completing “Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?”, participants will be able to: Explain the key characteristics of an oncolytic immunotherapy for advanced melanoma; Discuss the rationale for combini

Versha Banerji, MD, FRCPC - Raising the Bar: The Evolving Role of BTK Inhibitors in CLL Management

Dec 12 2024 27 mins  
Visit https://www.peervoice.com/XMR860 to view the entire programme with slides. After completing “Versha Banerji, MD, FRCPC - Raising the Bar: The Evolving Role of BTK Inhibitors in CLL Management”, participants will be able to: Discuss the evolving role of BTK inhibitors in the management of chronic lymphocytic leukemia (CLL) and how the latest evidence may inform their use;

Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer

Dec 12 2024 20 mins  
Visit https://www.peervoice.com/YVF860 to view the entire programme with slides. After completing “Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer”, participants will be able to: Identify common adverse events associated with the use of TROP2-directed agents in the management of adv

Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations

Nov 21 2024 17 mins  
Visit https://www.peervoice.com/WQK860 to view the entire programme with slides. After completing “Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations”, participants will be able to: Describe resistance mechanisms with targeted therapies for patient

John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis

Nov 21 2024 20 mins  
Visit https://www.peervoice.com/TBB860 to view the entire programme with slides. After completing “John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis”, participants will be able to: Recognize the significant symptom- and treatment-related burdens associated with cytopeni

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Nov 15 2024 18 mins  
Visit https://www.peervoice.com/KAX860 to view the entire programme with slides. After completing “Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours”, participants will be able to: Discuss best practices in HER2 testing of solid tumours; and Interpret the clinical significance of HER2 scores on therapeutic management.